They are developing activity-based sensing (ABS) probes for fluorescence and bioluminescence imaging of dynamic transition metal pools, chemoproteomic identification and biochemical characterization of new metalloprotein targets, and drug discovery to treat disease within the lens of metalloplasias. We work across cell, zebrafish, and mouse models to study transition metal signaling in cancer, obesity and fatty liver disease, and neurodegenerative diseases.